🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Primary Objective: * To describe the safety profile of the SP MenB vaccine...
Status
Terminated
Location
Lakeview Clinical Research Site Number : 8400029
Start Date
2021-03-29
Trial ID
NCT04825223
Treatments Being Tested
The purpose of this study is: To assess whether there are differences in a...
Status
Completed
Location
Health Protection Agency
Start Date
2008-02
Trial ID
NCT00625677
Treatments Being Tested
The purpose of this study is to assess the immunogenicity and safety of GSK...
Status
Completed
Location
GSK Investigational Site
Start Date
2012-02-06
Trial ID
NCT01506193
Treatments Being Tested
The purpose of the study is to evaluate the immune responses of UK infants ...
Status
Completed
Location
Hertfordshire Primary Care Trusts
Start Date
2005-04
Trial ID
NCT00197808
Treatments Being Tested
This study was aimed to explore safety and immunogenicity of two formulatio...
Status
Completed
Location
Multiple Locations
Start Date
2006-09
Trial ID
NCT00381615
The purpose of this study is to evaluate the safety, immunogenicity and ind...
Status
Completed
Location
Vaccine Evaluation Center
Start Date
2004-09
Trial ID
NCT00262002
Treatments Being Tested
Persistence of antibodies and kinetics of B cell response in healthy childr...
Status
Completed
Location
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road
Start Date
2006-04
Trial ID
NCT00310713
Treatments Being Tested
The purpose of this study is to assess the safety in terms of fever (rectal...
Status
Completed
Location
GSK Investigational Site
Start Date
2007-04-25
Trial ID
NCT00463437
CD46 is an exciting new therapeutic target in prostate cancer, with the ant...
Status
Active Not Recruiting
Location
University of California, San Francisco
Start Date
2022-03-18
Trial ID
NCT05245006
The proposed study was aimed to assess the immunogenicity, safety, tolerabi...
Status
Completed
Location
Grässl
Start Date
2008-03
Trial ID
NCT00657709